United Kingdom Biotechnology & Medical Research

Silence Therapeutics PLC (SLN)

Track

Silence Therapeutics PLC has recorded no insider trading activity within the last three months. The most recent transactions occurred on April 16, 2021, when several executives and directors, including the CEO and CFO, executed multiple share purchases. These historical acquisitions represent the final documented market movements by company leadership.
Ticker: SLN Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Silence Therapeutics PLC. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Craig Tooman Chief Financial Officer Officer
Transaction date
Purchase
Price
410.40
Quantity 77,013
Value US$2,149,889
Mark Rothera Chief Executive Officer and Executive Director Executive Director
Transaction date
Purchase
Price
498.27
Quantity 11,645
Value US$3,384,412
Dave Lemus Non-Executive Director Executive Director
Transaction date
Purchase
Price
290.65
Quantity 84,141
Value US$2,672,066
Michael Davidson Non-Executive Director Executive Director
Transaction date
Purchase
Price
23.09
Quantity 4,331
Value US$100,003
Steven Romano Non-Executive Director Executive Director
Transaction date
Purchase
Price
23.09
Quantity 4,331
Value US$100,003
Mark Rothera Chief Executive Officer Officer
Transaction date
Purchase
Price
18.20
Quantity 5,700
Value US$103,740
Dr. Steven Romano Non-Executive Director Executive Director
Transaction date
Purchase
Price
5.58
Quantity 4,500
Value US$25,113
Alistair Gray Non-Executive Director Executive Director
Transaction date
Purchase
Price
3.97
Quantity 1,258
Value £4,992
Dr. Giles Campion Executive Director Executive Director
Transaction date
Purchase
Price
4.04
Quantity 4,945
Value £19,978
David Lemus Non-Executive Director Executive Director
Transaction date
Purchase
Price
4.00
Quantity 1,250
Value £5,000
James Ede-Golightly Non-Executive Director Executive Director
Transaction date
Purchase
Price
4.09
Quantity 3,000
Value £12,262
Iain Ross Chairman Director
Transaction date
Purchase
Price
4.10
Quantity 9,750
Value £39,976
Iain Ross Executive Chairman Director
Transaction date
Purchase
Price
4.70
Quantity 15,800
Value £74,260
Rob Quinn Chief Financial Officer Officer
Transaction date
Sale
Price
4.04
Quantity 89,054
Value £359,778
Alistair Gray Non-Executive Director Executive Director
Transaction date
Purchase
Price
1.89
Quantity 3,171
Value £5,993
Dr. Steven Romano Non-Executive Director Executive Director
Transaction date
Purchase
Price
1.93
Quantity 10,000
Value £19,300
Iain Ross Non-Executive Chair Director
Transaction date
Purchase
Price
1.88
Quantity 25,000
Value £47,000
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2021-04-19 2021-04-16 B Purchase Craig Tooman

Chief Financial Officer

Officer
77,013
410.40
US$2,149,889 		77,013 410.40 US$2,149,889
2021-04-19 2021-04-16 B Purchase Mark Rothera

Chief Executive Officer and Executive Director

Executive Director
11,645
498.27
US$3,384,412 		11,645 498.27 US$3,384,412
2021-04-19 2021-04-16 B Purchase Dave Lemus

Non-Executive Director

Executive Director
84,141
290.65
US$2,672,066 		84,141 290.65 US$2,672,066
2021-04-19 2021-04-16 B Purchase Michael Davidson

Non-Executive Director

Executive Director
4,331
23.09
US$100,003 		4,331 23.09 US$100,003
2021-04-19 2021-04-16 B Purchase Steven Romano

Non-Executive Director

Executive Director
4,331
23.09
US$100,003 		4,331 23.09 US$100,003
2020-12-03 2020-12-01 B Purchase Mark Rothera

Chief Executive Officer

Officer
5,700
18.20
US$103,740 		5,700 18.20 US$103,740
2020-12-03 2020-11-30 B Purchase Dr. Steven Romano

Non-Executive Director

Executive Director
4,500
5.58
US$25,113 		4,500 5.58 US$25,113
2020-10-16 2020-10-14 B Purchase Alistair Gray

Non-Executive Director

Executive Director
1,258
3.97
£4,992 		1,258 3.97 £4,992
2020-10-12 2020-10-09 B Purchase Dr. Giles Campion

Executive Director

Executive Director
4,945
4.04
£19,978 		4,945 4.04 £19,978
2020-10-12 2020-10-09 B Purchase David Lemus

Non-Executive Director

Executive Director
1,250
4.00
£5,000 		1,250 4.00 £5,000
2020-10-12 2020-10-08 B Purchase James Ede-Golightly

Non-Executive Director

Executive Director
3,000
4.09
£12,262 		3,000 4.09 £12,262
2020-10-12 2020-10-08 B Purchase Iain Ross

Chairman

Director
9,750
4.10
£39,976 		9,750 4.10 £39,976
2020-05-29 2020-05-28 B Purchase Iain Ross

Executive Chairman

Director
15,800
4.70
£74,260 		15,800 4.70 £74,260
2020-05-12 2020-05-11 S Sale Rob Quinn

Chief Financial Officer

Officer
89,054
4.04
£359,778 		89,054 4.04 £359,778
2019-10-03 2019-10-02 B Purchase Alistair Gray

Non-Executive Director

Executive Director
3,171
1.89
£5,993 		3,171 1.89 £5,993
2019-10-02 2019-10-02 B Purchase Dr. Steven Romano

Non-Executive Director

Executive Director
10,000
1.93
£19,300 		10,000 1.93 £19,300
2019-09-30 2019-09-30 B Purchase Iain Ross

Non-Executive Chair

Director
25,000
1.88
£47,000 		25,000 1.88 £47,000
Explore more

More insider trading research around Silence Therapeutics PLC

More insider trades in United Kingdom
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in Europe